Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818431 | 1.00 | TRPC5 (0.47) | TRPC5P2RX3P2RX7PDK2KDM4E | |
| SCHEMBL20817781 | 0.91 | P2RX3 (0.44) | TRPC5P2RX3P2RX7PDK2KDM4E | |
| SCHEMBL25688490 | 0.87 | P2RX3 (0.49) | P2RX3PDK2HDAC1HDAC6 | |
| SCHEMBL25285486 | 0.86 | TRPC5 (0.52) | TRPC5P2RX7PDK2KDM4EALDH1A1 | |
| SCHEMBL29875887 | 0.84 | P2RX3 (0.53) | P2RX3HDAC1HDAC6 | |
| SCHEMBL25280265 | 0.83 | P2RX3 (0.45) | P2RX3HDAC1HDAC6 | |
| SCHEMBL25241849 | 0.82 | P2RX3 (0.42) | P2RX3PDK2 | |
| SCHEMBL20831355 | 0.82 | P2RX3 (0.46) | P2RX3 | |
| SCHEMBL20818259 | 0.82 | P2RX7 (0.44) | P2RX3P2RX7KDM4EALDH1A1GAA | |
| SCHEMBL20832044 | 0.82 | HDAC1 (0.42) | P2RX3P2RX7KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885P2RX3 370/4885P2RX7 270/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | TRPC5 1439/4885P2RX3 370/4885P2RX7 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.